Neobacin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neobacin

Property Description
Active Ingredients Bacitracin (Polypeptide) and Neomycin (Aminoglycoside)
Form Topical Powder and Ointment
Pharmacological Class Topical Antibiotic / Antibacterial Agent
Common Use (General) Preventing microbial presence
Origin Derived from microbial sources (Synthetic)

What Type of Medicine is Neobacin?

Neobacin is characterized as a fixed-dose combination product belonging to the pharmacological class of topical antibiotic agents, administered via the topical route. The two distinct active ingredientsBacitracin and Neomycin—are combined into dosage forms such as a topical powder or an ointment. This dual-agent structure provides a synergistic effect in localized microbial management.

The preparation is one of several products containing the combined Bacitracin and Neomycin formulation, a pairing notably distinct from similar “triple antibiotic” products. This specific combination focuses its broad spectrum antibacterial agents activity primarily through the established pathways of its two main constituents.


Composition: Understanding Bacitracin and Neomycin

The medication's effectiveness is defined by its active ingredients: Bacitracin (Bacitracin Zinc) and Neomycin (Neomycin Sulfate). Bacitracin is a polypeptide antibiotic that is primarily effective against Gram-positive bacteria, while Neomycin, an aminoglycoside, extends the broad spectrum antibacterial agents profile to include many Gram-negative bacteria.

The combined action of Bacitracin and Neomycin works by killing or preventing the growth of targeted bacteria. This synergy is critical because it offers a more comprehensive antimicrobial spectrum against the common mixture of pathogens often found on the skin surface.


What is the General Purpose of This Topical Antibiotic?

The primary purpose of Neobacin is to provide a robust bactericidal effect through its dual mechanism of effect, managing microbial presence and preventing microbial proliferation on the skin surface. Bacitracin interferes with bacterial cell wall synthesis, while Neomycin inhibits protein synthesis, ensuring that the therapeutic action is comprehensive. A typical, neutral use scenario involves the application of the topical powder or ointment to minor surface disruptions to prevent the establishment of microbial growth.

What side effects are possible with Neobacin?

Possible Side Effects and Safety Information

The safety profile for the Bacitracin and Neomycin combination is based on government regulatory documentation, defining both common localized reactions and potential serious systemic effects tied to absorption.

Documented Adverse Reactions

Adverse reactions are primarily associated with the skin and the immune system, with a recognized risk of serious systemic toxicity linked to the Neomycin component.

System-Organ Class Common Adverse Reaction Serious Adverse Reaction (Rare)
Skin & Subcutaneous Allergic contact dermatitis, itching (pruritus), redness (erythema), swelling, localized irritation, rash. Anaphylactoid reactions
Ear & Labyrinth - Permanent sensorineural hearing loss (Ototoxicity)
Renal & Urinary - Kidney damage (Nephrotoxicity)

Allergic sensitization to the medication is documented as a common reaction and may present as a failure of the condition to heal. The most serious reactions, such as ototoxicity and nephrotoxicity, are officially categorized as rare events that follow significant systemic absorption of Neomycin.

Safety Constraints and Special Populations

Official labeling defines specific conditions that increase the risk of systemic effects or allergic reactions:

  • Duration and Site Restrictions: The risk of systemic toxicity and superinfection (overgrowth of non-susceptible organisms) increases with prolonged use (e.g., longer than seven days) and application over large surface areas or to broken/raw skin (including deep wounds or serious burns).
  • Population Notes: Safety concerns are documented for certain groups. Infants and individuals with renal impairment are considered more susceptible to systemic toxicity. The use of this combination is generally not recommended during pregnancy or lactation due to the potential for Neomycin absorption and theoretical fetal harm.
  • Sensitization Risk: Allergic cross-reactions may occur with other aminoglycoside antibiotics, which can restrict their future use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose concerns for topical Neobacin (Bacitracin/Neomycin combination) are strictly focused on the potential for systemic absorption of the component Neomycin, particularly following accidental ingestion or application over extensive areas of compromised skin.

Regulatory documents highlight two major potential severe outcomes associated with Neomycin systemic absorption:

Overdose Manifestation Potential Severe Outcome
Systemic Absorption Ototoxicity (documented permanent hearing loss)
Accidental Ingestion Risk Nephrotoxicity (documented kidney damage)

These outcomes are classified as serious or life-threatening adverse events in official regulatory information. Acute presentations from accidental ingestion are described as potentially including stomach pain and vomiting. Exposure to the eyes may cause local redness or pain.

When Immediate Medical Help Is Required

Seek immediate medical attention for suspected overdose or any signs of severe systemic toxicity. It is mandated to contact emergency services or a Poison Control Center immediately if severe symptoms are observed, such as trouble breathing, collapse, or inability to be awakened.

In a hospital setting, official guidance describes management as primarily symptomatic and supportive treatment. This includes monitoring of vital signs and performing diagnostic tests. The regulatory labeling notes that the risk of toxicity is elevated in individuals with impaired renal function and in neonates.

Therapeutic Uses of Neobacin

The therapeutic uses of Neobacin are defined by its role as a topical antibacterial agent for managing and addressing the risk of localized microbial presence on the skin. Its application focuses on three core domains.

The medication is commonly used to address conditions marked by bacterial presence, including primary superficial infections such as impetigo and folliculitis, as well as secondary contamination in underlying dermatoses like infected eczema. In everyday scenarios, it is applied to minor cuts, scrapes, and superficial burns to assist in minimizing the risk of bacterial colonization. This prophylactic use contributes to improving comfort during recovery and supports general well-being during symptomatic phases.

Quick Fact: Relief for Localized Bacterial Symptoms

“This topical combination plays a role in managing microbial presence, which supports the process of easing the signs of active infection and assists with managing the associated symptoms related to physical discomfort.”

Eligibility and Restrictions for Use

The eligibility for Neobacin (Bacitracin and Neomycin) is strictly defined by regulatory documents, focusing on minimizing risks from systemic exposure and allergic reactions.

Contraindicated populations must not use the product. This includes individuals with known hypersensitivity to any component or related aminoglycoside antibiotics. The medicine is also contraindicated for application over large areas of the body, in the eyes, or in the external ear canal if the eardrum is perforated. Use is prohibited on skin lesions caused by tuberculous, fungal, or viral infections.

Restricted use applies to patients with kidney function impairment or existing hearing loss due to the potential for Neomycin component absorption, which carries a documented risk of toxicity. The product is not recommended for deep wounds, serious burns, or animal bites.

Regarding age, safety and effectiveness in pediatric patients are generally not established, and use is often restricted in children under 2 years. During pregnancy, use is conditional and should be administered only if clearly needed. Caution is advised during lactation as it is not known if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Neobacin, a topical combination of bacitracin and neomycin, primarily acts locally, meaning the risk of systemic drug interactions is generally low. However, systemic absorption can increase if the ointment is applied to large areas of damaged skin, deep wounds, or severe burns, which may lead to potential interactions.

Increased Risk of Toxicity

The following medications, if used concurrently with Neobacin, may increase the risk of nephrotoxicity (kidney damage) or ototoxicity (damage to the ear, potentially leading to hearing loss or vertigo) due to the neomycin component:

Drug Class Examples of Interacting Medicines
Other Aminoglycosides Gentamicin, Amikacin, Tobramycin
Potent Diuretics Furosemide, Ethacrynic acid
Other Nephrotoxic Drugs Cisplatin, Vancomycin, Amphotericin B

Neuromuscular Effects

There is a potential for additive neuromuscular blocking effects when Neobacin is used with muscle relaxants (e.g., tubocurarine, succinylcholine) often used during surgery. Patients with existing neuromuscular conditions, such as Myasthenia Gravis or Parkinson's disease, are particularly susceptible to increased muscle weakness.

Other Topical Products

Avoid using other topical antibiotics on the same area simultaneously, as this can increase the risk of sensitization or reduce the effectiveness of the treatment. Concurrent use of topical corticosteroids may increase the risk of localized skin adverse effects.

Mechanism of Action

How Neobacin Works: Mechanism of Action

Neobacin exerts its action through three distinct pharmacodynamic mechanisms. The primary effect is bactericidal, achieved by inhibiting bacterial protein synthesis. It binds specifically to the 30S ribosomal subunit , causing misreading of transfer RNA (tRNA) and premature polypeptide chain termination. This molecular cascade results in the irreversible cessation of bacterial viability.

Secondary, off-target mechanisms involve mammalian systems. Neobacin acts as an antagonist of presynaptic voltage-gated Ca^2+ channels, suppressing calcium influx necessary for synaptic vesicle fusion and neurotransmitter release. This action results in the failure of nerve signal transmission across the neuromuscular junction.

Further interaction occurs via the drug's polycationic nature, which enables binding to negatively charged phosphoinositide lipids in specialized cell membranes. This lipid disruption initiates organ-specific cellular dysfunction (e.g., in the inner ear and renal tubules), a key mechanistic constraint on systemic exposure.

Dosage and Administration Information

How to Use Neobacin: General Administration Guidelines

Neobacin, a topical antibacterial agent, is administered via the topical route and is available in formulations such as an ointment or a powder. The administration procedure outlines specific requirements for preparation, frequency, and duration of use.

The application procedure requires the skin surface to be cleaned and any material, such as pus or crusts, to be removed before the medicine is applied. The standard regimen for both adults and children two years of age and older is the application of a small amount or a thin layer to the affected area, typically repeated one to three times daily. Following application, the treated site may be optionally covered with a sterile bandage.

These instructions restrict the duration of use to a maximum of seven consecutive days, unless otherwise directed by a healthcare professional. Furthermore, the product is designated strictly for external use only and should not be used on large areas of the body, deep wounds, or serious burns. Use in infants under two years of age is generally not recommended due to the potential for systemic absorption of the ingredients.

The standard application procedure involves a clear, time-bound method for localized application, focusing the use of the topical agent to appropriate skin conditions and patient populations.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Combination Therapy

Research evidence has explored the combination of Drug A and Drug B for individuals experiencing chronic neuropathic pain. Studies evaluated whether this combination was associated with changes in pain scores. Research compared the combination to Drug C taken alone, which is used as a monotherapy for pain. Overall, the evidence suggests that the combination was studied for its potential in managing pain, with some participants noting changes in their symptoms.


Key Findings from Clinical Trials

Study Designs The trials included a mix of randomized, controlled trials (RCTs) and long-term observational studies. Research focused on adults diagnosed with chronic neuropathic pain for at least six months.

Study Endpoints

The primary endpoints of the studies focused on the change in pain severity (measured by the Visual Analog Scale or VAS) and the impact on a participant’s quality of life (using the SF-36 questionnaire).

Finding Monotherapy (Drug A) Combination Therapy (Drug A + Drug B)
Pain Severity Studies examined whether Drug A was associated with changes in the average severity of pain. Studies investigated the experience of participants receiving the combination therapy.
Quality of Life - Research evaluated whether participants receiving the combination reported changes in their ability to perform daily activities. Findings were mixed on the long-term changes to general well-being.

Safety and Tolerability

The most frequently experienced events reported by participants in the trials included dizziness, dry mouth, and somnolence. Research data addressed the study of this combination in participants with mild to moderate kidney impairment. Data for individuals with severe kidney impairment was limited or not studied. In the studies, participants generally started with a low dose.

Frequently Asked Questions (FAQ)

Common questions about Neobacin (FAQ)


Q: How long do the effects of Neobacin typically last?

Neobacin is a topical product intended for local action on the skin surface. Official administration instructions often recommend repeat applications, typically one to five times per day. The recommended application frequency suggests the effects are local and maintained through the scheduled applications, as described in the official product information.


Q: Can Neobacin be taken with herbal supplements like St. John's Wort?

Regulatory information primarily focuses on potential interactions with prescription and specific over-the-counter medications. While specific interactions with herbal supplements are not typically listed in the product labeling, official guidance emphasizes the importance of providing a complete list of all medications, herbs, non-prescription drugs, and dietary supplements to a healthcare provider for review.


Q: Can older adults use Neobacin?

Official regulatory documents indicate that there is generally no specific information available comparing the use of this topical combination in the elderly with use in other adult age groups. Therefore, use in older adults is generally described in line with the established short-term topical protocol.


Q: Is it necessary to have routine blood tests while taking Neobacin?

Official labeling does not typically specify routine blood testing for general topical use. Monitoring would be a clinical decision based on official concerns about systemic absorption, which carries a documented risk to the ears and kidneys if the product is used improperly on large, damaged areas of skin.


Q: Can Neobacin be taken on an empty stomach?

Neobacin is classified as a topical antibacterial agent and is for external use only. Since it is not swallowed or taken by mouth, its use is not influenced by whether the stomach is full or empty.


Q: Is Neobacin a type of pain reliever?

Official regulatory labeling classifies Neobacin as a topical antibiotic or antibacterial agent. Its primary stated purpose is to help prevent infection in minor cuts, scrapes, and burns, and it is not described as a medication for relieving pain.


Q: Can Neobacin be taken by children?

Official guidelines describe administration for children two years of age and older, consistent with the established method of application. However, regulatory sources also note that safety and effectiveness in younger pediatric patients, particularly those under two, are not fully established due to official concerns about systemic absorption of the ingredients.


Q: Are there any long-term health concerns associated with Neobacin?

Official instructions strictly restrict the duration of use to a maximum of seven consecutive days. The risk of serious adverse reactions, particularly systemic toxicity to the ear and kidney, is officially documented to increase with prolonged use beyond this maximum limit. The restriction to a maximum of seven consecutive days is defined in official documents unless alternative direction is provided by a healthcare professional.


Q: What happens if I miss a dose of Neobacin?

Official information describes that a missed application should be addressed by following the directions provided on the product label. It typically advises against doubling the application to make up for a missed one.


Q: Do I need a prescription to get Neobacin?

Official product information indicates that Neobacin is classified as an OTC (Over-the-Counter) Drug or marketed via an OTC monograph. It can be obtained without a prescription for its indicated short-term use.


Q: Is Neobacin meant for short-term or long-term use?

Official documents define the use of Neobacin as short-term. Regulatory instructions strictly limit the duration of use to a maximum of seven consecutive days, emphasizing its role as a temporary, topical antibacterial agent.


Q: Are there any specific foods I should avoid while on Neobacin?

As Neobacin is applied topically to the skin and is not swallowed, specific interactions with food are generally not listed in the official labeling. However, official guidance notes that questions regarding use and dietary concerns should be discussed with a healthcare professional.


Q: How does Neobacin physically work in the body?

Neobacin’s antibacterial effect comes from its two active ingredients working together. Bacitracin is described as preventing the targeted bacteria from building their cell walls, and Neomycin stops the bacteria from making essential proteins. This dual action is described as providing a broad spectrum of activity intended to manage the presence of common bacteria on the skin surface.


Q: Does Neobacin interact with alcohol?

Specific, prohibited interactions between topical Neobacin and alcohol are not typically listed in the official labeling. Official guidance indicates that questions about the use of medication with alcohol should be directed to a healthcare professional.


Q: What should I do if I experience a skin rash while taking Neobacin?

Regulatory guidance describes that if signs of irritation occur, such as a skin rash, redness, swelling, or itching, the protocol is to discontinue use and seek advice from a healthcare professional.


Q: Does Neobacin need to be taken at the same time every day?

Official information for antibacterial treatments often emphasizes the importance of using the medication at around the same times every day and not skipping any doses. Maintaining a consistent schedule supports the treatment protocol as described in the official product information.


Q: Is Neobacin a controlled substance?

Regulatory classification for Neobacin in the United States shows its DEA Schedule as None. This official classification means it is not designated as a controlled substance.


Q: Is Neobacin considered a high-risk medication?

Regulatory safety data sheets highlight warnings that the components of Neobacin are associated with risks like ototoxicity (hearing damage) and nephrotoxicity (kidney damage) if there is significant systemic exposure. These risks are rare but officially documented to increase with prolonged use or improper application to large areas of damaged skin.


Q: What is the maximum number of days Neobacin is typically used for?

The official protocol restricts the use to a maximum duration of seven consecutive days unless otherwise advised by a healthcare professional.


Q: Does the time of day I take Neobacin matter?

Official instructions focus on applying the medication at around the same times every day to help maintain a consistent effect over the course of treatment. Following a consistent schedule as described in the official product information is important for the short-term treatment protocol.


Q: Is Neobacin gluten-free?

While regulatory labeling lists the active ingredients, it does not always specify if inactive ingredients (excipients) contain gluten. However, some product-specific information indicates that the product is typically formulated without added gluten.


Q: Are there any specific warnings for Neobacin listed by the FDA or EMA?

Regulatory bodies officially highlight warnings related to the potential for systemic exposure of the Neomycin component. These cautions involve risks of ototoxicity (hearing damage) and nephrotoxicity (kidney damage) if the product is used on large or severely damaged areas of skin.


How should Neobacin be stored and disposed of?

How to Store and Dispose of Neobacin

Official regulatory labeling dictates specific conditions for storing and disposing of this topical antibiotic product, ensuring its stability and safety.

Storage and Handling

The medication must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with protection from excessive heat and moisture. It is mandatory to keep the product from freezing and to store it in a tightly closed container to maintain its integrity. The medicine must be kept out of the sight and reach of children in a secure, high location.

Condition Requirement
Temperature Controlled room temperature (Do not freeze)
Environment Protect from excessive light and moisture
Container Keep tightly closed

Disposal Instructions

Unused or expired product should not be used after the expiration date. For final disposition, the product must be disposed of according to local regulatory requirements. General guidelines advise against throwing medication into household wastewater or the trash unless directed by official regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neobacin found in:

A-Z Index: